2013年至2022年期间,澳大利亚多发性硬化症的疾病修饰疗法利用率和成本趋势
Ting Zhao1, Bruce V Taylor1, Julie A Campbell1
1Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, Hobart, TAS, Australia.
Multiple sclerosis (Houndmills, Basingstoke, England)
|December 20, 2023
概括
疾病修饰疗法 (DMT) 的使用和成本在多发性硬化症 (MS) 显著增加在澳大利亚超过十年. 更高效的DMT的增长最为明显,区域处方趋势在各州各不相同.
科学领域:
- 神经学 神经学
- 药物经济学 药物经济学
- 公共卫生 公共卫生
背景情况:
- 澳大利亚的多发性硬化症 (MS) 疾病修饰疗法 (DMT) 景观已经发生了显著的变化.
- 了解这些变化对于医疗保健规划和资源分配至关重要.
研究的目的:
- 评估澳大利亚10年 (2013-2022) 的MS相关DMT的利用和成本趋势.
- 调查澳大利亚各州和地区的DMT处方和成本的地理差异.
主要方法:
- 从药品福利计划 (2013-2022) 中提取了16种DMT的处方数据和成本.
- 采用描述性分析来检查基于人口的DMT使用情况,总成本和个体的DMT趋势.
- 将国家和州/地区数据进行比较,以便进行全面分析.
主要成果:
- 在全国范围内,每1万人口的DMT处方 (+125%) 和成本 (+164%) 显著增长.
- 更高效的DMT从总处方的54%增加到75%.
- 到2022年,ocrelizumab超过了fingolimod,成为最常被处方的DMT,有显著的州特定处方差异.
结论:
- 在过去的十年中,MS DMT的处方和相关成本一直在持续上升.
- 越来越多的高效DMT和区域处方差异突显了治疗模式的变化.
相关概念视频
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168